BAUSCH HEALTH AMERICAS, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- 3.1K
- Market Cap
- -
- Website
- http://www.bauschhealth.com
Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00230490
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT00162734
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 245
- Registration Number
- NCT00101725
- Locations
- ๐บ๐ธ
AGMG Clinical Research Institute, Anaheim, California, United States
๐บ๐ธLeBauer Research Associates, PA, Greensboro, North Carolina, United States
๐บ๐ธClinical Research Associates, Huntsville, Alabama, United States
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00093093
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐จ๐ฆToronto Western Hospital, Toronto, Ontario, Canada
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-07-07
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 515
- Registration Number
- NCT00086541
Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-09-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 354
- Registration Number
- NCT00045799
- Locations
- ๐บ๐ธ
Verdugo Hills Hospital, Burbank, California, United States
๐บ๐ธWellstar Kennestone Hospital, Marietta, Georgia, United States
๐บ๐ธPAB Clinical Research, Brandon, Florida, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath